Tag: MEDI8897

AZ’ RSV drug bags EMA PRIME, FDA Breakthrough statuses

by Anna Smith | Feb 5, 2019 | News | 0

AstraZeneca’s MEDI8897 has been granted access to both the European Medicines Agency (EMA) PRIME (PRIority MEdicines) scheme, and the US Food and Drug Administration’s (FDA) Breakthrough Therapy Designation (BTD).

AZ and Sanofi link on RSV vaccine

by Selina McKee | Mar 3, 2017 | News | 0

AstraZeneca’s MedImmune is partnering with Sanofi’s vaccines arm Sanofi Pasteur on the development and commercialisation of its experimental monoclonal antibody MEDI8897 for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.